Multiple Regression Analysis of the Influence of Factors Affecting Duration of Myelosupression and Intensity of Complications After HDC
| Endpoints . | Predictors . | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Age . | BMI . | Carboplatin3-150 . | Physical Performance3-151 . | Stem Cells3-152 . | Trainingρ . | . | . | . | . | . | . | ||||||
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
| β | P | β | P | β | P | β | P | β | P | β | P | |||||||
| Loss of physical performance3-155 | 0.27 | .05 | 0.13 | .32 | 0.08 | .52 | 0.26 | .06 | −0.04 | .70 | 0.31 | .01 | ||||||
| Duration of neutropenia (d) | −0.28 | .02 | −0.03 | .76 | 0.15 | .20 | −0.17 | .18 | −0.20 | .08 | 0.29 | .01 | ||||||
| Duration of thrombopenia (d) | 0.05 | .44 | 0.04 | .69 | 0.16 | .13 | −0.10 | .24 | 0.21 | .09 | 0.24 | .07 | ||||||
| No. of platelets transfusions | 0.05 | .70 | 0.05 | .69 | 0.16 | .19 | −0.10 | .43 | 0.01 | .90 | 0.25 | .05 | ||||||
| Intensity of pain3-154 | −0.15 | .23 | −0.15 | .24 | −0.04 | .72 | −0.11 | .42 | 0.16 | .18 | 0.26 | .03 | ||||||
| Intensity of diarrhea3-154 | 0.06 | .60 | −0.01 | .95 | 0.17 | .18 | 0.10 | .46 | 0.16 | .21 | 0.27 | .02 | ||||||
| Duration of hospitalization (d) | 0.03 | .80 | 0.16 | .21 | 0.02 | .81 | −0.15 | .24 | −0.18 | .13 | 0.24 | .04 | ||||||
| Endpoints . | Predictors . | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Age . | BMI . | Carboplatin3-150 . | Physical Performance3-151 . | Stem Cells3-152 . | Trainingρ . | . | . | . | . | . | . | ||||||
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
| β | P | β | P | β | P | β | P | β | P | β | P | |||||||
| Loss of physical performance3-155 | 0.27 | .05 | 0.13 | .32 | 0.08 | .52 | 0.26 | .06 | −0.04 | .70 | 0.31 | .01 | ||||||
| Duration of neutropenia (d) | −0.28 | .02 | −0.03 | .76 | 0.15 | .20 | −0.17 | .18 | −0.20 | .08 | 0.29 | .01 | ||||||
| Duration of thrombopenia (d) | 0.05 | .44 | 0.04 | .69 | 0.16 | .13 | −0.10 | .24 | 0.21 | .09 | 0.24 | .07 | ||||||
| No. of platelets transfusions | 0.05 | .70 | 0.05 | .69 | 0.16 | .19 | −0.10 | .43 | 0.01 | .90 | 0.25 | .05 | ||||||
| Intensity of pain3-154 | −0.15 | .23 | −0.15 | .24 | −0.04 | .72 | −0.11 | .42 | 0.16 | .18 | 0.26 | .03 | ||||||
| Intensity of diarrhea3-154 | 0.06 | .60 | −0.01 | .95 | 0.17 | .18 | 0.10 | .46 | 0.16 | .21 | 0.27 | .02 | ||||||
| Duration of hospitalization (d) | 0.03 | .80 | 0.16 | .21 | 0.02 | .81 | −0.15 | .24 | −0.18 | .13 | 0.24 | .04 | ||||||
Table 3 shows the β coefficients and the significance of a multivariable linear regression analyzing the influence of several predictors to the intensity of complications following chemotherapy, duration of myelosupression, and duration of hospitalization. P values are for the comparison with 0 (the values obtained by the null hypothesis).
Total dose of carboplatin.
Maximal physical performance (in km/h) on treadmill test by admission.
Number of reinfunded blood stem cells.
ρ Coded as training group = 0 and control group = 1.
Loss of physical performance during hospitalization (expressed as percentage of the physical performance on admission).
According to the WHO scale.